Related Experiment Video
Updated: Jul 8, 2026

An Open-Source Normothermic Perfusion System Designed for Research Scientists
Published on: July 18, 2025
Considerations on prevention of phlebitis and venous pain from intravenous prostaglandin E(1) administration by
Emiko Kohno1, Mayumi Nishikata, Noboru Okamura
1Department of Pharmacy, Kansai Medical University Takii Hospital, Fumizono-cho, Moriguchi, Osaka, Japan. kohnoe@takii.kmu.ac.jp
Abstract:
Prostaglandin E(1) (PGE(1); Alprostadil Alfadex) is a potent vasodilator and inhibitor of platelet aggregation used to treat patients with peripheral vascular disease. The main adverse effects of intravenous PGE(1) administration, phlebitis and venous pain, arise from the unphysiologically low pH of infusion solutions. When PGE(1) infusion solutions with a pH value greater then 6 are used, phlebitis and venous pain are considered to be avoidable. Beginning with a PGE(1) infusion solution with pH greater than 6, we add the amount of 7% sodium bicarbonate needed to bring the solution to pH 7.4 if phlebitis or venous pain develops. In the present study we established a convenient nomogram showing the relationship between the titratable acidity of various infusion solutions and the volume of 7% sodium bicarbonate required to attain pH 7.4 for preventing the phlebitis and venous pain associated with PGE(1) infusion.
Related Concept Videos
Venous Thrombosis IV: Nursing Management
Venous Thrombosis III: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Artery Disease V: Postoperative Nursing Management
Varicose Veins II: Diagnostic Studies and Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins